Physician profile
Richard G Moore
NPI 1932125895
$123,547.16
in general payments reported to CMS, 2019-2025
6 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $17K · 2021: $6,975 · 2022: $34K · 2023: $16K · 2024: $20K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,740.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujirebio Diagnostics, Incorporated | $120,174.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,397.50 | 2019 | |
| Glaxosmithkline, LLC. | $975.00 | 2021 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.